[SCHEDULE 13G/A] Evolent Health, Inc SEC Filing

Rhea-AI Filing Summary

Evolent Health, Inc. Schedule 13G/A shows Eventide Asset Management, LLC and two individuals jointly report beneficial ownership of 4,086,852 shares of Class A common stock, equal to 3.5% of the class. Eventide (organized in Delaware) discloses sole voting and dispositive power over the 4,086,852 shares while Finny Kuruvilla and Robin C. John each report shared voting and dispositive power over the same block. The filing relies on Rule 13d-1(k)(1) for a joint statement, includes certifications that the position was acquired in the ordinary course of business and not to influence control, identifies CUSIP 30050B101, and lists signatures dated August 14, 2025. The reporting address is One International Place, Boston, MA.

Positive

• Clear disclosure: Reports ownership of 4,086,852 shares representing 3.5% of Class A stock.
• Governance clarity: Filing details which reporting party holds sole versus shared voting and dispositive power and includes a joint-filing agreement under Rule 13d-1(k)(1).

Negative

• None.

Insights

Financial Analyst

TL;DR: Eventide reports a 3.5% stake (4.09M shares) in EVH; disclosure is routine and shows no declared intent to seek control.

The filing documents a modest, sub-5% position with Eventide holding sole voting and dispositive power while two individuals are reported with shared powers. At 3.5% of the class, this is below common control thresholds and is classified as ownership of 5 percent or less. The certification states the stake was acquired in the ordinary course of business and not to influence control, which supports a neutral market impact absent further announcements.

Corporate Governance Expert

TL;DR: Joint filing under Rule 13d-1(k)(1) clarifies coordination and voting arrangements; transparency improves governance visibility but shows no control shift.

The agreement among Eventide, Finny Kuruvilla and Robin C. John and the attached Rule 13d-1(k)(1) exhibit provide clear documentation of how voting and dispositive powers are allocated. Disclosure of sole versus shared powers helps stakeholders assess potential influence. Because the position is 3.5% and the filing includes a disclaimer against seeking control, this appears to be a transparency-focused disclosure rather than an activist or control-seeking event.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Evolent Health, Inc.

(Name of Issuer)

Class A Common Stock, par value $0.01 per share

(Title of Class of Securities)

30050B101

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 30050B101

1

Names of Reporting Persons

Eventide Asset Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,086,852.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,086,852.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,086,852.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.5 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 30050B101

1

Names of Reporting Persons

Finny Kuruvilla, M.D. Ph. D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,086,852.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,086,852.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,086,852.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.5 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 30050B101

1

Names of Reporting Persons

Robin C. John

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,086,852.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,086,852.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,086,852.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.5 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Evolent Health, Inc.
(b)	Address of issuer's principal executive offices: 1812 North Moore St, Suite 1705, Arlington, VA, 22209
Item 2.
(a)	Name of person filing: (i) Eventide Asset Management, LLC ("Eventide") (ii) Finny Kuruvilla, M.D., Ph.D. ("Kuruvilla") (iii) Robin C. John ("John")
(b)	Address or principal business office or, if none, residence: Eventide, Kuruvilla and John: One International Place, Suite 4210 Boston, Massachusetts 02110
(c)	Citizenship: Eventide: Delaware Kuruvilla: United States John: United States
(d)	Title of class of securities: Class A Common Stock, par value $0.01 per share
(e)	CUSIP No.: 30050B101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: (i) Eventide: 4,086,852 (ii) Kuruvilla: 4,086,852 (iii) John: 4,086,852
(b)	Percent of class: (i) Eventide: 3.5% (ii) Kuruvilla: 3.5% (iii) John: 3.5%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: (1) Eventide: 4,086,852 (2) Kuruvilla: 0 (3) John: 0
	(ii) Shared power to vote or to direct the vote: (1) Eventide: 0 (2) Kuruvilla: 4,086,852 (3) John: 4,086,852
	(iii) Sole power to dispose or to direct the disposition of: (1) Eventide: 4,086,852 (2) Kuruvilla: 0 (3) John: 0
	(iv) Shared power to dispose or to direct the disposition of: (1) Eventide: 0 (2) Kuruvilla: 4,086,852 (3) John: 4,086,852
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Eventide Asset Management, LLC

Signature:	/s/ Peter J. Luiso
Name/Title:	Peter J. Luiso, General Counsel
Date:	08/14/2025

Finny Kuruvilla, M.D. Ph. D.

Signature:	/s/ Finny Kuruvilla, M.D., Ph. D.
Name/Title:	Finny Kuruvilla, M.D., Ph. D.
Date:	08/14/2025

Robin C. John

Signature:	/s/ Robin C. John
Name/Title:	Robin C. John
Date:	08/14/2025

Exhibit Information

EXHIBIT 1 WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in writing that such Statement or amendments thereto is filed on behalf of each of them; NOW, THEREFORE, the parties hereto agree as follows: Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph. D. and Robin C. John do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file a Statement on Schedule 13G relating to their ownership of the Common Stock of the Issuer, and do hereby further agree that said Statement on Schedule 13G shall be filed on behalf of each of them. Eventide Asset Management, LLC Date: August 14, 2025 By: /s/ Peter J. Luiso Name: Peter J. Luiso Title: General Counsel Date: August 14, 2025 Finny Kuruvilla, M.D., Ph. D. By: /s/ Finny Kuruvilla, M.D., Ph. D. Name: Finny Kuruvilla, M.D., Ph. D. Date: August 14, 2025 Robin C. John By: /s/ Robin C. John Name: Robin C. John

FAQ

What stake does Eventide report in Evolent Health (EVH)?

Eventide reports beneficial ownership of 4,086,852 shares, representing 3.5% of Class A common stock.

When was the Schedule 13G/A signed for EVH?

Signatures on the filing are dated August 14, 2025.

Who are the reporting persons on the EVH Schedule 13G/A?

The reporting persons are Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph.D., and Robin C. John.

Which reporting person holds sole voting power over the shares?

Eventide Asset Management, LLC reports sole voting and sole dispositive power over the 4,086,852 shares.

Does the filing indicate an intent to influence control of EVH?

The filing includes certifications stating the shares were acquired and are held in the ordinary course of business and not to change or influence control.

What CUSIP and event date triggered this Schedule 13G/A for EVH?

The CUSIP is 30050B101 and the date of the event requiring the filing is June 30, 2025.